Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist

Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions
Shahdad Azmoon, Dominick J Angiolillo

Abstract

Dual antiplatelet therapy with aspirin plus a P2Y(12) receptor inhibitor is the cornerstone of treatment for patients with acute coronary syndrome and in those undergoing percutaneous coronary intervention. Clopidogrel is the most widely used P2Y(12) receptor inhibitor. Despite the clinical benefits associated with adjunctive clopidogrel therapy, a considerable number of patients continue to experience recurrent cardiovascular events. Importantly, the interindividual response to clopidogrel is variable and is affected by multiple factors, including genetic polymorphisms and drugs that interfere with the conversion of clopidogrel to its active metabolite. The individual variability to clopidogrel-induced antiplatelet effects has significant clinical implications that can result in an increased risk of atherothrombotic recurrences, including stent thrombosis. The introduction of novel P2Y(12) receptor inhibitors, such as prasugrel or ticagrelor, characterized by more potent and consistent platelet inhibitory effects, represents an opportunity for clinicians to consider these alternative therapies to overcome the limitations of clopidogrel. Understanding the strategies and implications of switching antiplatelet treatment regimens ...Continue Reading

References

Aug 25, 2001·The New England Journal of Medicine·S YusufUNKNOWN Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators
Nov 19, 2002·JAMA : the Journal of the American Medical Association·Steven R SteinhublUNKNOWN CREDO Investigators. Clopidogrel for the Reduction of Events During Observation
Jul 17, 2007·Thrombosis Research·Steven R SteinhublWendell S Akers
Sep 18, 2007·Journal of the American College of Cardiology·Gianluca CampoRoberto Ferrari
Nov 6, 2007·The New England Journal of Medicine·Stephen D WiviottUNKNOWN TRITON-TIMI 38 Investigators
Feb 7, 2008·JAMA : the Journal of the American Medical Association·P Michael HoJohn S Rumsfeld
Sep 1, 2009·The New England Journal of Medicine·Lars WallentinMona Thorsén
Nov 17, 2009·The New England Journal of Medicine·Robert A HarringtonDeepak L Bhatt
Nov 17, 2009·The New England Journal of Medicine·Deepak L BhattUNKNOWN CHAMPION PLATFORM Investigators
Jan 19, 2010·Lancet·Christopher P CannonUNKNOWN PLATelet inhibition and patient Outcomes Investigators
Jan 22, 2010·Revista española de cardiología·Dominick J Angiolillo, José Luis Ferreiro
Feb 9, 2010·Expert Review of Cardiovascular Therapy·Davide CapodannoDominick J Angiolillo
Mar 4, 2010·Circulation Journal : Official Journal of the Japanese Circulation Society·Dominick J AngiolilloShinya Goto
Jul 9, 2010·Future Cardiology·Masafumi UenoDominick J Angiolillo
Jul 31, 2010·Expert Review of Cardiovascular Therapy·Masafumi UenoDominick J Angiolillo
Dec 15, 2010·Expert Opinion on Investigational Drugs·Salvatore D TomaselloDominick J Angiolillo
Mar 12, 2011·Journal of the American College of Cardiology·Eric R BatesDominick J Angiolillo
Apr 23, 2011·JACC. Cardiovascular Interventions·Dominick J Angiolillo, Masafumi Ueno
Jan 19, 2012·JAMA : the Journal of the American Medical Association·Dominick J AngiolilloUNKNOWN BRIDGE Investigators

❮ Previous
Next ❯

Citations

Jul 23, 2013·EuroIntervention : Journal of EuroPCR in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·Mirjam KeßlerWolfgang Koenig
Feb 18, 2014·European Journal of Internal Medicine·Fanny BonhommeJean-Luc Reny
May 10, 2015·Vascular Pharmacology·Monica VerdoiaUNKNOWN Novara Atherosclerosis Study Group (NAS)
Oct 5, 2013·International Journal of Cardiology·Tsung O Cheng, Dong Zhao
Aug 19, 2015·Nature Reviews. Cardiology·Fabiana RolliniDominick J Angiolillo
Dec 24, 2015·Clinical Pharmacology and Therapeutics·J F PetersonK B Johnson
May 17, 2013·Journal of the American Heart Association·Michelle A Berny-LangAndrew L Frelinger
Mar 25, 2014·Journal of Thrombosis and Thrombolysis·Guido ParodiDavid Antoniucci
Jul 20, 2021·Journal of Cardiovascular Medicine·Monica VerdoiaUNKNOWN Novara Atherosclerosis Study Group (NAS)

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
David Vivas, Dominick J Angiolillo
Future Cardiology
Antonio Tello-MontoliuDominick J Angiolillo
American Heart Journal
Dominick J AngiolilloTheodore A Bass
© 2021 Meta ULC. All rights reserved